ClinicalTrials.gg

Program

SSGJ-613

A development code. Also written as “SSGJ-613 100 mg Q12W”, “SSGJ-613 200 mg Q12W” and “SSGJ-613 100 mg Q4W”.

Its studies are mostly in Arthritis, Gouty · Arthritis, Juvenile, led by 3SBio.

Furthest: phase 2, since Jul 12, 20263 company-led studies, 2 open or runningNext primary completion: Aug 11, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
3SBio32 open or runningphase 2since Jul 12, 2026Aug 17, 2021Aug 11, 2027phase 2 · NCT07708181

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 17, 2021First study: phase 1 study in Arthritis, JuvenileFirst studyNCT05027373 · 34 enrolled · China
  2. Jul 20, 2023Phase 1 study in Arthritis, GoutyNCT05966701 · 36 planned · China
  3. Jul 12, 2026Phase 2 study in Arthritis, GoutyPhase 2 reachedNCT07708181 · 200 planned

Ahead

  1. Aug 11, 2027Primary completion: phase 2 study in Arthritis, GoutyNCT07708181

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07708181Arthritis, Gouty2Not yet recruitingAug 11, 2027200
NCT05966701Arthritis, Gouty · China1Not yet recruitingMar 10, 202436
NCT05027373Arthritis, Juvenile · China1UNKNOWNApr 30, 202234

How it is read

Names in the registry

  • “SSGJ-613”, 2 entries
  • “SSGJ-613 100 mg Q12W”, 1 entry
  • “SSGJ-613 200 mg Q12W”, 1 entry
  • “SSGJ-613 100 mg Q4W”, 1 entry

Codes read as this program: SSGJ613.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.